Doctor, Patient Adoption of PGx Testing Increases in PBM-Initiated Programs, Medco Reports at ASHG
November 10, 2010
Doctor, Patient Adoption of PGx Testing Increases in PBM-Initiated Programs, Medco Reports at ASHG
The study found that when doctors and their patients were educated about PGx-guided dosing for warfarin and tamoxifen in a pharmacy-initiated personalized medicine program, the testing rate increased 45-fold for warfarin and seven-fold for tamoxifen.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Fate of Medco's Personalized Medicine Programs Uncertain Under Express Scripts' Acquisition Plan
July 27, 2011 / Pharmacogenomics Reporter - Medco's Observational Studies May Provide Blueprint for Dx Evidentiary Methods Beyond RCTs
August 19, 2009 / Pharmacogenomics Reporter - Following Merger, Express Scripts May Cut Back Medco's Personalized Medicine Programs
May 9, 2012 / Pharmacogenomics Reporter - Does Lack of PGx Link in Recent Studies Foreshadow End of CYP2D6 Genotyping for Tamoxifen?
March 14, 2012 / Pharmacogenomics Reporter - FDA Looks into Pradaxa Bleeding Risk; What Does it Mean for PGx-Guided Warfarin Dosing?
December 14, 2011 / Pharmacogenomics Reporter